



PRESS RELEASE

For Immediate Release

**Corgenix to Exhibit New AspirinWorks® Test
at AAFP 2007 Meeting in Chicago**

DENVER, Colo. — September 26, 2007 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its new AspirinWorks® Test Kit at the American Academy of Family Physicians (AAFP) 2007 Annual Scientific Assembly. The exhibit takes place October 4 – 6 at McCormick Place in Chicago.

The AspirinWorks test was launched nationwide in June 2007 following FDA 510(k) clearance. The test measures the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin's target). The stickier the blood platelets, the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

“This conference gives us a chance to meet face-to-face with physicians who are on the front line in American health care,” said Corgenix' Clinical Affairs Director Gordon Ens. “With AspirinWorks now available to virtually every physician in the U.S., this is a tremendous opportunity to educate the physicians in the value of the information that the AspirinWorks product provides and how the test results can affect treatment decisions.”

Corgenix representatives will be on-hand during AAFP 2007 in booth #1482 to answer questions about Corgenix' full line of diagnostic tests as well as AspirinWorks, including availability of the test, the latest supporting clinical data and how to order the test.

The AspirinWorks® Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Dan Snyders
Vice President, Public Relations Supervisor
Armada Medical Marketing

Phone: 303-623-1190 x 230
dan@armadamedical.com